MedTrace Logo

Czech AATD Registry

NCT05178277 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-01-05

No results posted yet for this study

Summary

Alpha-1-antitrypsin deficiency is the most common congenital disease of the respiratory system, leading to early pulmonary emphysema or bronchiectasis. Pulmonary involvement significantly accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders.

The AATD Registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency.

The aim of the AATD National Registry is to collect and analyze clinical data in patients with alpha-1 antitrypsin deficiency.

Conditions

  • Alpha-1-antitrypsin Deficiency

Sponsors & Collaborators

  • Masaryk University

    collaborator OTHER

  • Thomayer University Hospital

    lead OTHER

Principal Investigators

  • Jan MD Chlumsky, PhD · Thomayer University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2033-12-31
Completion
2035-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05178277 on ClinicalTrials.gov